Physician profile
Sayed A Hashemee
NPI 1124057856
$1,502.28
in general payments reported to CMS, 2019-2025
18 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $103 · 2021: $182 · 2022: $328 · 2023: $143 · 2024: $186 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $358.59 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $212.69 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $150.00 | 2019 | |
| Eisai INC. | $143.93 | 2024-2025 | |
| Glaxosmithkline, LLC. | $137.11 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $66.14 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $63.41 | 2019 | |
| Amarin Pharma, INC. | $57.98 | 2019 | |
| Amgen INC. | $57.43 | 2019 | |
| Medtronic, INC. | $50.16 | 2022 | |
| Organogenesis INC. | $45.64 | 2022 | |
| Mylan Specialty L.P. | $38.63 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $33.18 | 2020-2023 | |
| Pfizer INC. | $27.22 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $18.79 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $15.00 | 2024 | Eliquis |
| Phathom Pharmaceuticals, INC. | $14.64 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayed Hashemee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.